Genenta Science S.P.A. Terminates Work Statement No. 1 with AGC Biologics

SEC Filing 6-K (0001493152-25-011539)

On August 1, 2025, Genenta Science S.P.A. notified AGC Biologics S.p.A. of its intent to terminate Work Statement No. 1, which was part of the Second Amendment to the Development and Master Services Agreement. This termination will eliminate Genenta's commitment to a dedicated GMP suite effective August 1, 2026. However, AGC will continue to manufacture certain drug products for Genenta in shared suites. The Second Amendment to the agreement was originally entered into on December 30, 2024, and the initial Development and Master Services Agreement was effective as of March 6, 2019, with a prior amendment on March 5, 2024.